Daré Bioscience (NASDAQ:DARE – Get Free Report) is expected to announce its earnings results before the market opens on Monday, March 31st. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $1.00 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.
Daré Bioscience Stock Performance
NASDAQ:DARE opened at $2.88 on Friday. The company has a market capitalization of $25.06 million, a P/E ratio of -4.88 and a beta of 1.38. The stock’s 50 day moving average price is $3.07 and its 200 day moving average price is $3.29. Daré Bioscience has a 52 week low of $2.67 and a 52 week high of $7.56.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Daré Bioscience in a research note on Tuesday, December 17th.
About Daré Bioscience
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Featured Stories
- Five stocks we like better than Daré Bioscience
- There Are Different Types of Stock To Invest In
- MarketBeat Week in Review – 03/24 – 03/28
- How Investors Can Find the Best Cheap Dividend Stocks
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- What to Know About Investing in Penny Stocks
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
